|Bid||3.07 x 800|
|Ask||3.26 x 1000|
|Day's Range||3.12 - 3.26|
|52 Week Range||1.59 - 5.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.33|
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has entered into a second amendment to the second statement of work (“SOW Two”) under its Master Assay Development, Commercialization and Manufacturing Agreement with Qiagen Manchester Limited (“QML”). This second amendment enables the use of the investigational use only (“IUO”) assay developed in the initial-phase of SOW Two in additional disease indications. “We are very pleased to continue to expand our agreement and to take the next logical step in our immuno-oncology collaboration with the Pharma Partner and QML through the use of the existing IUO assay into multiple additional disease indications,” said Byron Lawson, Senior Vice President, Pharma Partnerships.
“We are pleased to welcome Michelle to our Board,” said TJ Johnson, Chief Executive Officer of HTG. “Michelle brings deep financial and accounting expertise, in addition to her extensive executive experience, making her insights invaluable as HTG continues its growth trajectory.
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced it launched its HTG EdgeSeq Precision Immuno-Oncology Panel and has delivered its first orders to translational and clinical researchers working in the field of cancer immunology and/or cancer immunotherapy. This Research Use Only profiling panel provides a large, comprehensive set of genes involved in the host immune response to tumors. While progress has been made in immuno-therapies, much work still remains on biomarker development to better identify patients who will respond or not respond to these therapies, and we believe our panel, with its 1,392 genes will go a long way in helping reach that goal,” said Mike Hrubiak, Senior Vice President of HTG’s Profiling Business Unit.
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Neos ...
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has entered into an amendment to the second statement of work (“SOW Two”) under its Master Assay Development, Commercialization and Manufacturing Agreement with Qiagen Manchester Limited (“QML”). SOW Two relates to a project for which HTG and QML are performing collaborative development services for what is expected to be a multi-stage project leading to the potential development and commercialization of an NGS-based companion diagnostic assay in support of one or more of the therapeutic development and commercialization programs of Bristol-Myers Squibb Company (“BMS”).
It is sloppy and slow out there with some computer algorithms jerking the indices around. There aren't any big earnings reports driving the action today and there is a mishmash of stocks moving around.
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 26.32% and -7.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Revenue increased 179% and 190%, respectively, compared to the three and six-month periods in the prior year. Call scheduled for today, August 7, at 4:30 pm ET. TUCSON, Ariz., Aug. 07, 2018-- HTG Molecular ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM ...
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with operations in Boston and Shanghai, today announced the completion of a master agreement where the companies have agreed to partner on the development of biomarkers associated with Oncologie’s Immuno-oncology pipeline. “We are honored to be working with Oncologie on biomarker development programs for their innovative pipeline of Immuno-oncology assets,” stated TJ Johnson HTG Chief Executive Officer.
TUCSON, Ariz., Aug. 01, 2018-- HTG Molecular Diagnostics, Inc., a provider of instruments, reagents, and services for molecular profiling applications, today announced TJ Johnson, Chief Executive Officer ...
TUCSON, Ariz., July 24, 2018-- HTG Molecular Diagnostics, Inc., a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial ...
Today, Zosano Pharma is trading at a stock price of $4.38, which represents ~5.92% growth from its closing price of $4.14 yesterday. $4.14 represented ~15% growth from the stock’s 52-week low of $3.61 on February 13. Zosano Pharma hit a 52-week high of $27.8 on July 18, 2017.
HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM): HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The US$97.03mRead More...
Today, WallStEquities.com evaluates the following Medical Laboratories and Research stocks: Agilent Technologies Inc. (NYSE: A), Biocept Inc. (NASDAQ: BIOC), Co-Diagnostics Inc. (NASDAQ: CODX), and HTG Molecular Diagnostics Inc. (NASDAQ: HTGM). Companies in the medical laboratories market are independent, commercial enterprises that provide information to healthcare professionals about the severity, onset, and reason of patients' physical ailments.
Positive seasonality for small caps and penny stocks has ended. Legacy Reserves LP ( LGCY) soared nearly 84% in the first two weeks of the month, posting a 3-year high, while solar manufacturer Enphase Energy, Inc. ( ENPH) broke out of a 2-month basing pattern and gained 40%. Enphase Energy, Inc. ( ENPH) posted an-all time high at $17.97 in September 2014 and broke down in May 2015, entering a brutal decline that ended at an all-time low at 65-cents in the second quarter of 2017.
Examining HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has metRead More...
The Russell-2000 small-cap index held up better than the S&P 500 or Nasdaq-100, with trade tensions favoring small domestic issues over multinational giants. Low-priced sector plays have gained ground as well, with a broad basket of penny stocks posting 52-week highs. Legacy Reserves LP ( LGCY) posted the most substantial returns on April’s penny stocks watch list, gaining nearly 18% in sympathy with energy sector buying interest.